University of Lille: coffee consumption and Alzheimer's risk — evidence and limitations

Initial note: This article was previously published and updated here according to scientific and informative criteria. The purpose is informational: it does not replace medical advice. [Update based on peer-reviewed literature with verified DOIs]

IN BRIEF

• Studies in mouse models indicate that caffeine can influence both tau and beta-amyloid deposits, with improved memory in mice in some experiments.
• Research in humans suggests associations between regular coffee consumption and lower cerebral amyloid accumulation or slower cognitive decline, but does not demonstrate certain causality.
• Proposed mechanisms include antagonism of adenosine receptors (especially A2A), anti-inflammatory effects, and antioxidant actions; uncertainty remains regarding the effective dose and the role of other coffee components.
• Evidence combines preclinical experiments, imaging studies, and observational meta-analyses; controlled clinical trials and intervention studies are needed to assess safety and clinical benefit.

Abstract: what does science say?

The relationship between caffeine consumption (mainly through coffee) and the risk of Alzheimer's disease has been studied on multiple fronts. Experiments in transgenic mice have shown that chronic caffeine administration can reduce the accumulation of abnormal proteins (tau or β-amyloid) and attenuate memory deficits in some animal models. Observational studies and research with brain imaging in humans have reported associations between regular coffee consumption and lower amyloid accumulation or slower cognitive decline in specific cohorts, but there is still no clinical evidence that coffee prevents or cures Alzheimer's. Plausible mechanisms include blocking adenosine receptors (A2A), reducing inflammatory processes and oxidative stress, and other metabolic effects. However, the evidence is heterogeneous in terms of dose, exposure time, type of beverage, and studied populations; therefore, controlled clinical studies, standardized intake measures, and analyses that separate the effect of caffeine from that of other coffee compounds are needed.

Main section

Experimental evidence in animal models

Research on mouse models of Alzheimer's has represented the first level of evidence for the effect of caffeine on neuropathological characteristics. In particular, in a transgenic model with tau accumulation, chronic caffeine treatment administered in water showed improvements in spatial memory and favorable alterations in tau protein modifications, as well as a reduction in pro-oxidative and pro-inflammatory markers, suggesting a multi-factorial effect on brain tissue. These results are consistent with other studies on amyloidosis models that found a decrease in β-amyloid and cognitive improvement after prolonged caffeine exposure, including partial memory restoration in aged mice with already high amyloid load. It should be noted that the dosages used in rodents (calculated for human equivalence) and the administration methods differ significantly from human consumption habits, and that mouse models do not fully reproduce the complexity of human Alzheimer's. Therefore, although preclinical evidence is plausible and replicated in various laboratories, it constitutes an experimental basis that requires controlled translation into human clinical studies [1][2][3].

Observational evidence and imaging studies in humans

The epidemiological literature includes meta-analyses and longitudinal studies investigating the association between coffee or caffeine consumption and the risk of cognitive decline or dementia. Some meta-analyses and reviews report an inverse association, suggesting a reduced risk in categories with moderate-to-high consumption, but the results are not uniform and causality cannot be established from observational studies [6]. Studies with biological markers and imaging provide more direct clues: one cohort found that a historical intake of ≥2 cups/day was associated with lower positivity for β-amyloid deposition on PET; another long-term study found that higher coffee consumption is associated with slower amyloid accumulation and less rapid cognitive decline in specific cognitive domains. These studies suggest correlations consistent with preclinical data, but remain vulnerable to confounders (diet, lifestyle, smoking, genetic characteristics) and problems in measuring exposure [4][5][6].

Plausible biological mechanisms

Some proposed mechanisms directly link the pharmacological action of caffeine to the biology of Alzheimer's. The main known target of caffeine in the nervous system is the blockade of adenosine receptors, particularly A2A; the modulation of these receptors affects synaptic plasticity, microglial inflammation, and neuronal stress pathways, providing a plausible way to limit synaptotoxicity induced by β-amyloid or related toxic processes [7]. In addition, caffeine and coffee components can reduce oxidative stress and influence enzymes involved in amyloid and tau metabolism, contributing to multiple simultaneous effects. Recent systematic reviews and Mendelian genetic studies, however, provide conflicting results: genetic evidence linking plasma caffeine levels to Alzheimer's risk is suggestive but not conclusive, highlighting the need for integrated approaches to separate the effect of caffeine alone from that of other compounds present in coffee [8][9].

PRACTICAL SECTION

What it means in practice

For the general public, the body of evidence suggests that regular and moderate coffee consumption may be associated with better cognitive outcomes in some contexts, but there is currently no clinical indication to recommend coffee as a prevention or treatment for Alzheimer's. Important variables include the quantity and timing of consumption, the type of beverage (filtered coffee, espresso, tea), the presence of other bioactive components in coffee, and individual characteristics (age, comorbidities, medications, caffeine metabolism). Given the potential for adverse effects (insomnia, tachycardia, anxiety, drug interactions), any choice about consumption should be evaluated in the context of individual health. In summary: the evidence is interesting and biologically plausible, but insufficient for therapeutic recommendations; following general health guidelines and discussing any concerns with your doctor remains the best practice [6][8].

KEY POINTS TO REMEMBER

• There is solid experimental evidence that caffeine modifies pathological markers and memory in mouse models of Alzheimer's, including studies showing effects on tau and β-amyloid. [1][2][3]
• Observational studies and imaging investigations in humans show associations between coffee consumption and lower amyloid load or slower cognitive decline in some cohorts, but do not demonstrate causality. [4][5][6]
• The most frequently cited biological mechanisms involve the blockade of adenosine A2A receptors, anti-inflammatory and antioxidant actions; however, the molecular complexity of coffee makes it difficult to attribute the effect to a single compound. [7][8]
• There are currently no sufficient controlled clinical trials to prescribe caffeine or coffee as a treatment for Alzheimer's; clinical research is needed. [9]

Limitations of the evidence

It is essential to distinguish between types of studies and what each can legitimately show. Observational studies assess associations and are subject to confounders and biases (e.g., reverse causation, misclassification of exposure, socioeconomic factors). Animal experiments provide mechanistic information but do not guarantee the same response in humans. Reviews and meta-analyses aggregate heterogeneous data; they can support a signal but not establish cause-and-effect. Common methodological limitations include variability in the definition of "coffee consumption," the absence of objective measures (e.g., plasma caffeine levels) in many studies, differences in individual caffeine metabolism, and unrepresentative populations. To move from plausibility to clinical proof, randomized intervention studies and dose-response studies with clear clinical outcomes and standardized biological measurements are needed [6][9].

Editorial conclusion

Research on caffeine and Alzheimer's represents an interesting example of translation from molecular biology and animal models to population studies and human imaging studies. The evidence is consistent in signaling a possible protective role of caffeine or coffee on Alzheimer's-related processes, but the extent of the evidence does not yet reach the level required for clinical interventions or therapeutic recommendations. The conduct of controlled trials and studies that separate the effect of caffeine from that of other coffee constituents remains a priority, as well as further investigations into dosages, exposure times, and populations that could benefit. In the meantime, for the general population, moderate coffee consumption can be considered part of an overall healthy lifestyle, taking into account possible individual adverse effects.

Editorial note

This article updates previous content by integrating peer-reviewed literature verified via DOI. The information provided is for educational purposes and does not replace personalized clinical advice. For decisions on diagnosis, treatments, or dietary changes, always consult a healthcare professional.

SCIENTIFIC RESEARCH

1. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller C.E., Buée L, Blum D. Beneficial effects of caffeine in a transgenic model of Alzheimer’s disease‑like Tau pathology. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2014.03.027. [1]
2. Arendash GW, Schleif W, Rezai‑Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta‑amyloid production. Neuroscience. https://doi.org/10.1016/j.neuroscience.2006.07.021. [2]
3. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai‑Zadeh K, Tan J, Citron BA, Lin X, Echeverria V, Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid‑β levels in aged Alzheimer's disease mice. Journal of Alzheimer's Disease. https://doi.org/10.3233/JAD-2009-1087. [3]
4. Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Jung G, et al. Coffee intake and decreased amyloid pathology in human brain. Translational Psychiatry. https://doi.org/10.1038/s41398-019-0604-5. 2019. [4]
5. Gardener SL, Rainey‑Smith SR, Villemagne VL, Fripp J, Doré V, Bourgeat P, et al. Higher coffee consumption is associated with slower cognitive decline and less cerebral Aβ‑amyloid accumulation over 126 months: Data from the Australian Imaging, Biomarkers, and Lifestyle Study. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2021.744872. [5]
6. Larsson SC, Orsini N. Coffee Consumption and Risk of Dementia and Alzheimer’s Disease: A Dose‑Response Meta‑Analysis of Prospective Studies. Nutrients. https://doi.org/10.3390/nu10101501. 2018. [6]
7. Laurent B, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β‑amyloid peptides via p38 MAPK pathway. The Journal of Neuroscience. https://doi.org/10.1523/JNEUROSCI.3728-09.2009. [7]
8. Kolahdouzan M, Hamadeh MJ. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.12684. 2017. [8]
9. Larsson SCL, Lee SJ, Lindstrom SCL, S.C.L. Plasma caffeine levels and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomization study. Nutrients. https://doi.org/10.3390/nu14091697. 2022. [9]